Royal Bank of Canada Decreases Stake in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Royal Bank of Canada reduced its stake in Regeneron Pharmaceuticals by 29.7%, selling 85,740 shares, and now owns approximately $128.9 million worth of the company's stock.
• Regeneron recently reported $12.89 EPS for the last quarter, surpassing analyst expectations, with a revenue of $3.68 billion, an increase of 3.6% year-over-year.
• The company declared a quarterly dividend of $0.88 per share, scheduled for payment on September 3rd, reflecting a 0.6% yield.

Royal Bank of Canada lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 29.7% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 203,197 shares of the biopharmaceutical company's stock after selling 85,740 shares during the period. Royal Bank of Canada owned 0.19% of Regeneron Pharmaceuticals worth $128,874,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of REGN. GAMMA Investing LLC increased its position in shares of Regeneron Pharmaceuticals by 89,825.0% during the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock worth $517,291,000 after purchasing an additional 814,713 shares during the last quarter. Nuveen LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth about $343,764,000. Pacer Advisors Inc. increased its position in shares of Regeneron Pharmaceuticals by 2,296.9% during the 1st quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock worth $258,366,000 after purchasing an additional 390,374 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of Regeneron Pharmaceuticals by 171.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company's stock worth $305,311,000 after purchasing an additional 303,785 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Regeneron Pharmaceuticals by 30.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 982,064 shares of the biopharmaceutical company's stock worth $699,554,000 after purchasing an additional 226,952 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Up 1.1%

Shares of REGN traded up $6.16 during midday trading on Friday, hitting $573.38. The company had a trading volume of 959,753 shares, compared to its average volume of 949,804. The company's 50-day simple moving average is $562.59 and its 200-day simple moving average is $584.62. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The firm has a market capitalization of $60.77 billion, a P/E ratio of 14.45, a P/E/G ratio of 1.90 and a beta of 0.35. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,170.58.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.43 by $4.46. The business had revenue of $3.68 billion during the quarter, compared to analysts' expectations of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business's quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter last year, the business posted $11.56 EPS. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.87%.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Jefferies Financial Group raised their price objective on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a "buy" rating in a research report on Wednesday, August 27th. JPMorgan Chase & Co. cut their price objective on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a research report on Monday, June 9th. Rothschild & Co Redburn began coverage on Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They set a "buy" rating and a $890.00 price objective for the company. Sanford C. Bernstein lifted their target price on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an "outperform" rating in a research report on Wednesday, August 27th. Finally, BMO Capital Markets lifted their target price on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a research report on Monday, August 4th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $817.67.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.